Skip To Main Content
Sonja Loges on Muck Rack

Sonja Loges

As seen in: Nature, MDPI, Cell Stem Cell, The Lancet

Get in touch with Sonja

Contact Sonja, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Precision oncology without borders: the role of biobanking in integrating Africa’s genetic diversity into global genomic research

|
By Lina Winter, Mamoudou Maiga, Sonja Loges, Frederik Marmé, Saidou Balam, Christoph Brochhausen, Haby Konaté, Fousseyni Diarra, Bakrou Kamaté, Cheick B. Traoré
| Nature Verified
Abstract Cancer mortality in sub-Saharan Africa is projected to double by 2030. African populations exhibit the highest genetic diversity worldwide, impacting cancer susceptibility, tumor biology, and therapeutic response, yet remain critically underrepresented in biomedical research.
Open in Who Shared Issue with article?

Embedding equity in Germany's National Lung Cancer Screening roll-out: a call to action

|
By Sonja Loges, Connie Hoe
| The Lancet Verified
Get full text access Log in, subscribe or purchase for full access. References 1. Bray, F ∙ Laversanne, M ∙ Sung, H ∙ et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin. 2024; 74:229-263 2. de Koning, HJ ∙ van der Aalst, CM ∙ de Jong, PA ∙ et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial N Engl J Med. 2020; 382:503-513 3. Belachew, SA ∙ Bizuayehu, HM ∙ Diaz, A ∙ et al.
Open in Who Shared Issue with article?

Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial | Nature Communications

|
By Sonja Loges, Michael Heuser, Maike Collienne, Charles D Imbusch, Niklas Beumer, David Micklem, Grerk Sutamtewagul
| Nature Verified
Abstract Beyond first line, the prognosis of relapsed/refractory (R/R) acute myeloid leukemia (AML) patients is poor with limited treatment options. Bemcentinib is an orally bioavailable, potent, highly selective inhibitor of AXL, a receptor tyrosine kinase associated with poor prognosis, chemotherapy resistance and decreased antitumor immune response.
Open in Who Shared Issue with article?
See all 5 articles